{"id":"https://openalex.org/W3000403758","doi":"https://doi.org/10.1002/art.41201","title":"Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States","display_name":"Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States","publication_year":2020,"publication_date":"2020-01-13","ids":{"openalex":"https://openalex.org/W3000403758","doi":"https://doi.org/10.1002/art.41201","mag":"3000403758","pmid":"https://pubmed.ncbi.nlm.nih.gov/31943866"},"language":"en","primary_location":{"id":"doi:10.1002/art.41201","doi":"https://doi.org/10.1002/art.41201","is_oa":true,"landing_page_url":"https://doi.org/10.1002/art.41201","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.41201","source":{"id":"https://openalex.org/S4210186158","display_name":"Arthritis & Rheumatology","issn_l":"2326-5191","issn":["2326-5191","2326-5205"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.41201","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100615887","display_name":"Seoyoung C. Kim","orcid":"https://orcid.org/0000-0002-2517-3579","observed_orcids":["https://orcid.org/0000-0002-2517-3579"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Seoyoung C. Kim","raw_affiliation_strings":["Brigham and Women's Hospital"],"raw_orcid":"https://orcid.org/0000-0002-2517-3579","affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035621209","display_name":"Ameet Sarpatwari","orcid":"https://orcid.org/0000-0001-5043-6206","observed_orcids":["https://orcid.org/0000-0001-5043-6206"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ameet Sarpatwari","raw_affiliation_strings":["Brigham and Women's Hospital"],"raw_orcid":"https://orcid.org/0000-0001-5043-6206","affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080151435","display_name":"Joan E. Landon","orcid":"https://orcid.org/0009-0009-7433-1826","observed_orcids":["https://orcid.org/0009-0009-7433-1826"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joan E. Landon","raw_affiliation_strings":["Brigham and Women's Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009688412","display_name":"Rishi J. Desai","orcid":"https://orcid.org/0000-0003-0299-7273","observed_orcids":["https://orcid.org/0000-0003-0299-7273"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rishi J. Desai","raw_affiliation_strings":["Brigham and Women's Hospital and Harvard Medical School, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0003-0299-7273","affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital and Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":1.9233,"has_fulltext":true,"cited_by_count":23,"citation_normalized_percentile":{"value":0.86926444,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":99},"biblio":{"volume":"72","issue":"6","first_page":"1036","last_page":"1038"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.9223999977111816,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.9223999977111816,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.05310000106692314,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.00930000003427267,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tumor-necrosis-factor-inhibitors","display_name":"tumor necrosis factor inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/biosimilar-infliximab","display_name":"infliximab biosimilar","score":0.8949999809265137},{"id":"https://openalex.org/keywords/treatment-costs","display_name":"treatment costs","score":0.7099999785423279},{"id":"https://openalex.org/keywords/medication-use","display_name":"medication use","score":0.7429999709129333},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.8560000061988831}],"concepts":[{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.5669195055961609},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5530701875686646},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.4448506832122803},{"id":"https://openalex.org/C2778805511","wikidata":"https://www.wikidata.org/wiki/Q1713","display_name":"Citation","level":2,"score":0.43173182010650635},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.4189388155937195},{"id":"https://openalex.org/C161191863","wikidata":"https://www.wikidata.org/wiki/Q199655","display_name":"Library science","level":1,"score":0.41353753209114075},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.33592480421066284},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2555941343307495},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.18695488572120667}],"mesh":[{"descriptor_ui":"D000069285","descriptor_name":"Infliximab","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000069285","descriptor_name":"Infliximab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000079424","descriptor_name":"Tumor Necrosis Factor Inhibitors","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000079424","descriptor_name":"Tumor Necrosis Factor Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010342","descriptor_name":"Patient Acceptance of Health Care","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D012216","descriptor_name":"Rheumatic Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012216","descriptor_name":"Rheumatic Diseases","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017048","descriptor_name":"Health Care Costs","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/art.41201","doi":"https://doi.org/10.1002/art.41201","is_oa":true,"landing_page_url":"https://doi.org/10.1002/art.41201","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.41201","source":{"id":"https://openalex.org/S4210186158","display_name":"Arthritis & Rheumatology","issn_l":"2326-5191","issn":["2326-5191","2326-5205"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatology","raw_type":"journal-article"},{"id":"pmid:31943866","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31943866","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & rheumatology (Hoboken, N.J.)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1002/art.41201","doi":"https://doi.org/10.1002/art.41201","is_oa":true,"landing_page_url":"https://doi.org/10.1002/art.41201","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.41201","source":{"id":"https://openalex.org/S4210186158","display_name":"Arthritis & Rheumatology","issn_l":"2326-5191","issn":["2326-5191","2326-5205"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/5","display_name":"Gender equality","score":0.44999998807907104}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320308347","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94"},{"id":"https://openalex.org/F4320315359","display_name":"Arnold Ventures","ror":null}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3000403758.pdf","grobid_xml":"https://content.openalex.org/works/W3000403758.grobid-xml"},"referenced_works_count":3,"referenced_works":["https://openalex.org/W2610308940","https://openalex.org/W2890474965","https://openalex.org/W2899736308"],"related_works":["https://openalex.org/W3009289544","https://openalex.org/W3045632627","https://openalex.org/W2328043835","https://openalex.org/W7006766469","https://openalex.org/W2999942204","https://openalex.org/W3080930643","https://openalex.org/W2556301403","https://openalex.org/W2088402398","https://openalex.org/W2602013378","https://openalex.org/W7099546166"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":8}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-01-23T00:00:00"}